Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CODOX-M/IVAC in Relapsed/Refractory ALL
NCT00774332Phase 2
Key facts
- Status
- Unknown
- Start
- Jun 2006
- Primary completion
- Jun 2006
- Countries
- 1
- Sponsor
- Japan Adult Leukemia Study Group
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands, Covalent Small Molecules
- Conditions
- acute lymphoblastic leukemia (ALL)
01
Overview
Phase 2, open-label, single-arm trial of cyclophosphamide, doxorubicin, vincristine, methotrexate, cytarabine and 2 more in acute lymphoblastic leukemia (ALL), sponsored by Japan Adult Leukemia Study Group. Primary endpoints: Complete Remission Rate, Duration of Complete Remission and 3 more. Status: unknown.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
CODOX-M/IVAC
Single arm receiving CODOX-M/IVAC regimen
03
Endpoints
Primary
Complete Remission Rate
Duration of Complete Remission
Disease-Free Survival
Overall Survival
Toxicities
Beyond the preview
Go deeper on NCT00774332.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00774332.